Allogeneic Placental-Derived Product Candidates

Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic products for indications where the demonstrated properties of such cells could provide an advantage, both in terms of development (sourcing and proliferation) and potential efficacy (affinity). In selecting indications, we evaluate where the biological properties of the placenta positions our products for success, and where there is a clearly defined regulatory pathway that provides the potential for accelerated development to address unmet patient need.

CLINICAL PIPELINE

Hematological Malignancies	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
CYNK-001	pNK	Unmodified	AML
CYNK-301	pNK	IL15 + Marrow Homing + CAR	AML
CYCART-19	pT	CD19 + TCR KO	NHL, MCL
CYCART-201	pT	CD16 + TCR KO + mAb	NHL, MCL
Solid Tumor	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
CYCART-201	pT	CD16 + TCR KO + mAb	HER2+ Tumors
CYNK-302	pNK	CD16 + IL15 + CAR	NSCLC
Autoimmune & Degenerative Disease	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
APPL-001	MLASC	TF KO	Crohn’s Other potential indications
pEXO-001	pEXO	Unmodified	Osteoarthritis

BIOMATERIAL PIPELINE

Degenerative Diseases	Indication	Discovery	Regulatory		Brands
Placental Connective Tissue Matrix	Integumental Tissue Replacement
Amniotic Membrane Allograft	Wound Covering
Tri-Layer Amniotic Membrane Allograft	Wound Covering
Tri-Layer Amniotic Membrane Allograft	Protective Cover
Connective Tissue Wrap	Tendon
Placental Extracellular Matrix Osteoconductive Properties	Bone, Spine, Dental
Degenerative Diseases	Indication	Discovery	Regulatory	Regulatory	Brands
Extracellular Matrix Particulates	Aesthetics
Extracellular Matrix Particulates	Osteoarthritis

CLINICAL PIPELINE

Hematological Malignancies	Platform	Functionality	Indication
CYNK-001	pNK	Unmodified	AML
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Hematological Malignancies	Platform	Functionality	Indication
CYNK-301	pNK	IL15 + Marrow Homing + CAR	AML
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Hematological Malignancies	Platform	Functionality	Indication
CYCART-201	pT	CD19 + TCR KO	NHL, MCL
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Hematological Malignancies	Platform	Functionality	Indication
CYCART-201	pT	CD16 + TCR KO + mAb	NHL,MCL
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Solid Tumor	Platform	Functionality	Indication
CYCART-201	pT	CD16 + TCR KO + mAb	HER2+ Tumors
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Solid Tumor	Platform	Functionality	Indication
CYNK-302	pNK	CD16 + IL15 + CAR	NSCLC
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Autoimmune & Degenerative Disease	Platform	Functionality	Indication
APPL-001	MLASC	TF KO	Crohn's Other potential indications
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

Autoimmune & Degenerative Disease	Platform	Functionality	Indication
pEXO-001	pEXO	Unmodified	Osteoarthritis
Discovery	IND-Enabling	Phase 1/2	Phase 2/3

BIOMATERIAL PIPELINE

Degenerative Disease		Indication
Placental Connective Tissue Matrix		Integumental Tissue Replacement
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Amniotic Membrane Allograft		Wound Covering
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Tri-Layer Amniotic Membrane Allograft		Wound Covering
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Tri-Layer Amniotic Membrane Allograft		Protective Cover
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Connective Tissue Wrap		Tendon
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Placental Extracellular Matrix Osteoconductive Properties		Bone, Spine, Dental
Preclinical	Regulatory		Phase 2

Degenerative Disease		Indication
Extracellular Matrix Particulates		Aesthetics
Preclinical	Regulatory	Phase 1	Phase 2

Degenerative Disease		Indication
Extracellular Matrix Particulates		Osteoarthritis
Preclinical	Regulatory	Phase 1	Phase 2

Developing Therapies for a Range of Diseases

Celularity is investigating allogeneic therapies that are ready-to-use and eliminate the need for matching patients with donors.

We believe we are only in the early stages of unlocking the full potential of the Celularity IMPACT platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).